Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Duchenne Muscular Dystrophy Market Report 2024

Duchenne Muscular Dystrophy Global Market Report 2024 – By Therapy (Mutation Suppression, Exon Skipping Approach), By Therapeutic Class (Molecular Based Therapies, Steroid Therapy), By Route of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

Duchenne Muscular Dystrophy Global Market Report 2024

Starting Price : $5000.00 | Pages : 175 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Duchenne Muscular Dystrophy Global Market Report 2023

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Duchenne Muscular Dystrophy Market Definition And Segments

Duchenne muscular dystrophy is a genetic disease that causes gradual muscle loss, affecting the skeletal, cardiac, and lung muscles. It is caused by a mutation in the gene responsible for producing dystrophin, a protein that is crucial for the healthy operation of muscles.

The main types of therapies included in duchenne muscular dystrophy are mutation suppression and exon skipping approach. Exon skipping is the most prevalent type of alternative splicing, in which introns and intervals on a pre-mRNA molecule that ordinarily function as exons of a gene are removed together when a final mRNA is formed. therapeutic classes included are molecular-based therapies and steroid therapy and the route of administration are oral, parenteral, and others. These are distributed through hospital pharmacies, online pharmacies, and retail pharmacies for use in end-users such as hospitals, homecare, specialty clinics, and others.

The duchenne muscular dystrophy market covered in this report is segmented –

1) By Therapy: Mutation Suppression, Exon Skipping Approach

2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, collaborative research initiatives.

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches.

The Role Of Duchenne Muscular Dystrophy Market In Chronic Disease Landscape

The increasing prevalence of chronic diseases is expected to propel the growth of the Duchenne muscular dystrophy market in the future. A chronic disease is a health issue or condition with long-lasting symptoms lasting for at least a year. The Duchenne muscular dystrophy contributes to the prevalence of chronic diseases by addressing the specific therapeutic needs of individuals with this genetic disorder, highlighting the broader significance of personalized medicine in managing and potentially mitigating the impact of chronic conditions. For instance, in January 2023, according to the National Institutes of Health (NIH), a U.S. government agency that conducts and supports biomedical and health-related research, the study projects a substantial rise in the prevalence of chronic diseases among the working-age population in the United States, with an estimated 99.5% increase in adults aged 50 years and older with at least one chronic disease from 2020 to 2035. Additionally, the prevalence of multimorbidity is expected to surge by 110.5% from 2020 to 2050, highlighting the growing health challenges faced by the working population. Therefore, the increasing prevalence of chronic diseases is driving the growth of the Duchenne muscular dystrophy market.

Personalized Medicine's Impact On Duchenne Muscular Dystrophy Market

The growing demand for personalized medicine is expected to propel the Duchenne muscular dystrophy market's growth in the future. Personalized medicine tailors medical treatment to an individual's unique characteristics, such as genetic makeup or lifestyle, resulting in more effective and precise healthcare outcomes. Personalized medicine is used to manage Duchenne muscular dystrophy (DMD), by tailoring treatments based on individual factors advances therapeutic efficacy and improves patient outcomes. For instance, in December 2023, according to a report by The Personalized Medicine Coalition (PMC), a US-based nonprofit organization that promotes the use of personalized medicine concepts, services, and products, personalized medicines constituted 35% of newly approved NMEs in 2021. They have consistently represented over a quarter of new therapeutics approved since 2015. Over the last six years, personalized medicines have consistently comprised more than a third of new drug approvals. Therefore, the growing demand for personalized medicine is driving the Duchenne muscular dystrophy market's growth.

Major companies operating in the duchenne muscular dystrophy market report are Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly and Company, Daiichi Sankyo Company Limited, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Acceleron Pharma Inc., FibroGen Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., CureVac N.V., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Nihon Pharmaceutical Co. Ltd., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

Technological Advancements Drive Growth In Duchenne Muscular Dystrophy Market

Technological advancements are a key trend gaining popularity in the Duchenne muscular dystrophy market. Major companies operating in the Duchenne muscular dystrophy market are focusing more on technological advancements and research and development to sustain their position in the market. For instance, in April 2021, according to the University of Texas Southwestern's s Hamon Center for Regenerative Science and Medicine, a US-based public academic health science center, launched a new type of gene therapy to treat mice with Duchenne muscular dystrophy (DMD) by using CRISPR-Cas9-based techniques to restore a significant portion of the dystrophin protein that is missing in many DMD patients. The scientists created several effective CRISPR-Cas9 nucleotide gene editing techniques to bypass the mistaken stop signal, restoring the creation of 97 % of the protein. They quickly investigated nucleotide gene editing techniques using cardiomyocytes produced from iPS cells of DMD patients, showing the restoration of the dystrophin protein.

Pioneering Gene Therapy For Duchenne Muscular Dystrophy Marks A Revolutionary Milestone In Treatment Innovation

Major companies operating in the Duchenne muscular dystrophy market are focusing on product innovations, such as the first gene therapy to treat Duchenne Muscular Dystrophy. This therapy involves introducing functional copies of the dystrophin gene into affected individuals to address the genetic mutation responsible for the progressive muscle degeneration characteristic of the disease. For instance, in June 2023, Sarepta Therapeutics, a US-based biopharmaceutical company that develops RNA-based treatments for rare and infectious diseases, announced FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy. This groundbreaking one-time treatment utilizes advanced gene therapy technology to address the genetic cause of the disease. Its significance lies in revolutionizing DMD treatment, representing a breakthrough from traditional supportive care approaches, potentially enhancing patients' quality of life and life expectancy while showcasing the transformative potential of gene therapy in addressing rare diseases.

Solid Biosciences Expands Neuromuscular And Cardiac Programs Through Acquisition Of AavantiBio

In December 2022, Solid Biosciences, a US-based based life sciences company focused on developing on advancing a portfolio of neuromuscular and cardiac programs acquired AavantiBio for an undisclosed amount. With this acquisition, the combined company will focus on developing variety of neuromuscular and cardiac programs, including SGT-003, Solid's next-generation gene transfer candidate for the treatment of Duchenne. AavantiBio, Inc. is a US-based biotechnology company focused on developing gene therapies to transform the lives of patients with rare genetic diseases.

North America was the largest region in the Duchenne muscular dystrophy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the duchenne muscular dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The duchenne muscular dystrophy market includes revenues earned by entities by providing respiratory therapy, physical therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The duchenne muscular dystrophy market research report is one of a series of new reports from The Business Research Company that provides Duchenne muscular dystrophy optical components market statistics, including Duchenne muscular dystrophy optical components industry global market size, regional shares, competitors with a Duchenne muscular dystrophy optical components market share, detailed Duchenne muscular dystrophy optical components market segments, market trends, and opportunities, and any further data you may need to thrive in the Duchenne muscular dystrophy optical components industry. This Duchenne muscular dystrophy optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Book your 30 minutes free consultation with our research experts

Contact Us
Duchenne Muscular Dystrophy Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $1.17 billion
Revenue Forecast In 2033 $1.61 billion
Growth Rate CAGR of 8.2% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc.; GlaxoSmithKline plc; Eli Lilly and Company; Daiichi Sankyo Company Limited; PerkinElmer Inc.; BioMarin Pharmaceutical Inc.; Nippon Shinyaku Co. Ltd.; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; Acceleron Pharma Inc.; FibroGen Inc.; Asklepios BioPharmaceutical Inc.; Catabasis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Bristol Myers Squibb Company; BridgeBio Pharma Inc.; CureVac N.V.; Rocket Pharmaceuticals Inc.; Italfarmaco SpA; Solid Biosciences Inc.; Avidity Biosciences Inc.; Fulcrum Therapeutics Inc.; Akashi Therapeutics Inc.; Nihon Pharmaceutical Co. Ltd.; WAVE Life Sciences Ltd.; Capricor Therapeutics Inc.; Santhera Pharmaceuticals Holding; Armagen Technologies Inc.; Dyne Therapeutics Inc.; Benitec Biopharma Limited; Edgewise Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Duchenne Muscular Dystrophy Market Characteristics

    3. Duchenne Muscular Dystrophy Market Trends And Strategies

    4. Duchenne Muscular Dystrophy Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Duchenne Muscular Dystrophy Market Size and Growth

    5.1. Global Duchenne Muscular Dystrophy Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Duchenne Muscular Dystrophy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Duchenne Muscular Dystrophy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Duchenne Muscular Dystrophy Market Segmentation

    6.1. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Mutation Suppression

    Exon Skipping Approach

    6.2. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Molecular Based Therapies

    Steroid Therapy

    6.3. Global Duchenne Muscular Dystrophy Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Parenteral

    Other Routes Of Administration

    6.4. Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Online Pharmacy

    Retail Pharmacy

    6.5. Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Homecare

    Specialty Clinics

    Other End-Users

    7. Duchenne Muscular Dystrophy Market Regional And Country Analysis

    7.1. Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Duchenne Muscular Dystrophy Market

    8.1. Asia-Pacific Duchenne Muscular Dystrophy Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Duchenne Muscular Dystrophy Market

    9.1. China Duchenne Muscular Dystrophy Market Overview

    9.2. China Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Duchenne Muscular Dystrophy Market

    10.1. India Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Duchenne Muscular Dystrophy Market

    11.1. Japan Duchenne Muscular Dystrophy Market Overview

    11.2. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Duchenne Muscular Dystrophy Market

    12.1. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Duchenne Muscular Dystrophy Market

    13.1. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Duchenne Muscular Dystrophy Market

    14.1. South Korea Duchenne Muscular Dystrophy Market Overview

    14.2. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Duchenne Muscular Dystrophy Market

    15.1. Western Europe Duchenne Muscular Dystrophy Market Overview

    15.2. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Duchenne Muscular Dystrophy Market

    16.1. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Duchenne Muscular Dystrophy Market

    17.1. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Duchenne Muscular Dystrophy Market

    18.1. France Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Duchenne Muscular Dystrophy Market

    19.1. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Duchenne Muscular Dystrophy Market

    20.1. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Duchenne Muscular Dystrophy Market

    21.1. Eastern Europe Duchenne Muscular Dystrophy Market Overview

    21.2. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Duchenne Muscular Dystrophy Market

    22.1. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Duchenne Muscular Dystrophy Market

    23.1. North America Duchenne Muscular Dystrophy Market Overview

    23.2. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Duchenne Muscular Dystrophy Market

    24.1. USA Duchenne Muscular Dystrophy Market Overview

    24.2. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Duchenne Muscular Dystrophy Market

    25.1. Canada Duchenne Muscular Dystrophy Market Overview

    25.2. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Duchenne Muscular Dystrophy Market

    26.1. South America Duchenne Muscular Dystrophy Market Overview

    26.2. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Duchenne Muscular Dystrophy Market

    27.1. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Duchenne Muscular Dystrophy Market

    28.1. Middle East Duchenne Muscular Dystrophy Market Overview

    28.2. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Duchenne Muscular Dystrophy Market

    29.1. Africa Duchenne Muscular Dystrophy Market Overview

    29.2. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Duchenne Muscular Dystrophy Market Competitive Landscape And Company Profiles

    30.1. Duchenne Muscular Dystrophy Market Competitive Landscape

    30.2. Duchenne Muscular Dystrophy Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. GlaxoSmithKline plc

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Eli Lilly and Company

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Daiichi Sankyo Company Limited

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. PerkinElmer Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Duchenne Muscular Dystrophy Market Other Major And Innovative Companies

    31.1. BioMarin Pharmaceutical Inc.

    31.2. Nippon Shinyaku Co. Ltd.

    31.3. Sarepta Therapeutics Inc.

    31.4. PTC Therapeutics Inc.

    31.5. Acceleron Pharma Inc.

    31.6. FibroGen Inc.

    31.7. Asklepios BioPharmaceutical Inc.

    31.8. Catabasis Pharmaceuticals Inc.

    31.9. Wave Life Sciences Ltd.

    31.10. Bristol Myers Squibb Company

    31.11. BridgeBio Pharma Inc.

    31.12. CureVac N.V.

    31.13. Rocket Pharmaceuticals Inc.

    31.14. Italfarmaco SpA

    31.15. Solid Biosciences Inc

    32. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking

    33. Global Duchenne Muscular Dystrophy Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market

    35. Duchenne Muscular Dystrophy Market Future Outlook and Potential Analysis

    35.1 Duchenne Muscular Dystrophy Market In 2028 - Countries Offering Most New Opportunities

    35.2 Duchenne Muscular Dystrophy Market In 2028 - Segments Offering Most New Opportunities

    35.3 Duchenne Muscular Dystrophy Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Duchenne Muscular Dystrophy Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: Pfizer Inc. Financial Performance
  • Table 77: GlaxoSmithKline plc Financial Performance
  • Table 78: Eli Lilly and Company Financial Performance
  • Table 79: Daiichi Sankyo Company Limited Financial Performance
  • Table 80: PerkinElmer Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Duchenne Muscular Dystrophy Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: Pfizer Inc. Financial Performance
  • Figure 77: GlaxoSmithKline plc Financial Performance
  • Figure 78: Eli Lilly and Company Financial Performance
  • Figure 79: Daiichi Sankyo Company Limited Financial Performance
  • Figure 80: PerkinElmer Inc. Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Read More

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Read More

The Microbiome Market Share, Market Size, And Growth Rate 2022

Read More

Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth

Read More

Generic Musculoskeletal Disorders Drugs Global Market Report 2024 – By Treatment Type (Medication, Therapy, Surgery, Other Treatment Types), By Disorder Type (Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types), By Route of Administration (Oral, Parenteral, Other Routes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Muscle Relaxant Drugs Global Market Report 2024 – By Drug Type( Facial Muscle Relaxant Drugs, Skeletal Muscle Relaxant Drugs, Neuromuscular Blocking Agents), By Formulation( Cyclobenzaprine, Carisoprodol, Chlorzoxazone, Metaxalone, Methocarbamol, Baclofen, Tizanidine, Orphenadrine, Dantrolene ), By Route of Administration( Oral, Injectable, Spray, Ointment), By End-User( Hospitals, Homecare, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Women’s Health Devices Global Market Report 2024 – By Product (Surgical, Diagnostics, Contraceptives, Labor and Delivery, Critical Care), By Type (Devices, Consumables), By Application (Cancer, Osteoporosis, Infectious Disease, Uterine Fibroids, Post-menopausal Syndrome, Pregnancy, Female Sterilization, Other Applications), By End-user (Hospitals, Obstetrics and Gynecology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Healthcare Services Global Market Report 2024 – By Type (Medical And Diagnostic Laboratory Services, Dental Services, Home Health Care And Residential Nursing Care Services, Residential Substance Abuse And Mental Health Facilities, Hospitals And Outpatient Care Centers, Physicians And Other Health Practitioners, All Other Ambulatory Health Care Services, Ambulance Services), By End User Gender (Male, Female), By Type of Expenditure (Public, Private) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Home Health Care And Residential Nursing Care Services Global Market Report 2024 – By Type (Home Health Care Providers, Retirement Communities, Nursing Care Facilities, Orphanages & Group Homes), By Type of Expenditure (Public, Private), By End User Gender (Male, Female) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Pharmacies and Healthcare Stores Global Market Report 2024 – By Type (Pharmacies And Drug Stores, Food (Health) Supplement Stores, Other Healthcare And Personal Care Stores), By Ownership (Retail Chain, Independent Stores), By drug type (Prescription Drugs, Over-The-Counter (OTC) Drugs) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Physicians And Other Health Practitioners Global Market Report 2024 – By Type (Specialist Doctors, Primary Care Doctors, Podiatrists, Physical Therapists, Optometrists, Chiropractors), By End User Gender (Male, Female), By Type of Expenditure (Public, Private) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Connected Healthcare Global Market Report 2024 – By Type (e-Prescription, mHealth Services, mHealth Devices ), By Function (Remote Patient Monitoring, Clinical Monitoring, Telemedicine, Other Functions ), By Application (Monitoring Applications, Diagnosis And Treatment, Education And Awareness, Healthcare Management, Wellness And Prevention ), By End Users (Hospitals And Clinics, Home Monitoring) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Frequently Asked Questions

What is the definition of the duchenne muscular dystrophy market?

Duchenne muscular dystrophy is a genetic disease that causes gradual muscle loss, affecting the skeletal, cardiac, and lung muscles. It is caused by a mutation in the gene responsible for producing dystrophin, a protein that is crucial for the healthy operation of muscles. For further insights on the duchenne muscular dystrophy market, request a sample here

How will the duchenne muscular dystrophy market drivers and restraints affect the duchenne muscular dystrophy market dynamics? What forces will shape the duchenne muscular dystrophy industry going forward?

The duchenne muscular dystrophy market major growth driver - the role of duchenne muscular dystrophy market in chronic disease landscape. For further insights on the duchenne muscular dystrophy market, request a sample here

What is the forecast market size or the forecast market value of the duchenne muscular dystrophy market ?

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, collaborative research initiatives. The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches. For further insights on the duchenne muscular dystrophy market, request a sample here

How is the duchenne muscular dystrophy market segmented?

The duchenne muscular dystrophy market is segmented
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-UsersFor further insights on the duchenne muscular dystrophy market, request a sample here

Which region has the largest share of the duchenne muscular dystrophy market? What are the other regions covered in the report?

North America was the largest region in the Duchenne muscular dystrophy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the duchenne muscular dystrophy market, request a sample here.

Who are the major players in the duchenne muscular dystrophy market?

Major companies operating in the duchenne muscular dystrophy market report are Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Acceleron Pharma Inc., FibroGen Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., CureVac N.V., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Nihon Pharmaceutical Co. Ltd., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc. For further insights on the duchenne muscular dystrophy market, request a sample here.

What are the key trends in the duchenne muscular dystrophy market?

Major trend in the duchenne muscular dystrophy market - pioneering gene therapy for duchenne muscular dystrophy marks a revolutionary milestone in treatment innovation. For further insights on the duchenne muscular dystrophy market, request a sample here.

What are the major opportunities in the duchenne muscular dystrophy market? What are the strategies for the duchenne muscular dystrophy market?

For detailed insights on the major opportunities and strategies in the duchenne muscular dystrophy market, request a sample here.

How does the duchenne muscular dystrophy market relate to the overall economy and other similar markets?

For detailed insights on duchenne muscular dystrophy market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the duchenne muscular dystrophy industry?

For detailed insights on the mergers and acquisitions in the duchenne muscular dystrophy industry, request a sample here.

What are the key dynamics influencing the duchenne muscular dystrophy market growth? SWOT analysis of the duchenne muscular dystrophy market.

For detailed insights on the key dynamics influencing the duchenne muscular dystrophy market growth and SWOT analysis of the duchenne muscular dystrophy industry, request a sample here.